How Nandrolone Decanoate Affects LDL Cholesterol

Nandrolone decanoate has a comparatively benign LDL profile for structural reasons that separate it from the oral class:

1. Injectable ester, no first-pass hepatic loading: The decanoate ester is cleaved slowly in muscle and adipose tissue, releasing nandrolone into systemic circulation. The liver never sees the concentrated portal bolus that a 17-alpha-alkylated oral delivers. Thompson (1989, PMID 2915439) established that this route difference, rather than androgenic potency, is what determines whether LDL rises.

2. Not 17-alpha-alkylated: Nandrolone decanoate carries a 17-beta ester rather than a 17-alpha-alkyl group, so it does not resist hepatic metabolism and does not produce the sustained hepatocyte androgen signal that downregulates LDL receptor expression.

3. Weak aromatisation, with a caveat: Nandrolone aromatises poorly compared with testosterone, so it provides little oestrogenic support for hepatic LDL receptors. In practice this matters less than expected because nandrolone is almost never run without a testosterone base, and the testosterone supplies the oestradiol.

4. Lipoprotein(a) reduction: Both Sattler (2002, PMID 12388173) and Hartgens (2004, PMID 15155420) documented Lp(a) falling on nandrolone. Sattler measured decreases of 7 mg/dL, and Hartgens saw Lp(a) fall from 103 to 65 U/L on 200 mg/week. Lp(a) is an independent, largely diet-resistant cardiovascular risk factor, so this is a genuinely favourable change, though its net clinical weight against the HDL fall is unresolved.

Where nandrolone does its damage: HDL, and progesterone receptor-mediated effects. Not LDL.

High-dose nandrolone decanoate for 12 weeks (Sattler 2002, PMID 12388173, 30 HIV-positive men, randomised to nandrolone alone or nandrolone plus resistance training):

• Total cholesterol: no significant change
• LDL cholesterol: no significant change
• LDL phenotype (particle size distribution): no significant change in the nandrolone-alone group; the training group gained 5.2 angstroms of LDL particle size, a favourable shift
• HDL cholesterol: -8.7 mg/dL (nandrolone alone) and -10.6 mg/dL (nandrolone plus training), both p less than 0.001
• Lipoprotein(a): -7.3 mg/dL and -6.9 mg/dL respectively
• Triglycerides: fell by 66 mg/dL across the whole population
• Most changes reverted to baseline within 2 months of stopping, except HDL in the training group

At 200 mg/week for 8 weeks (Hartgens 2004, PMID 15155420, randomised double-blind, placebo-controlled, 16 bodybuilders):

• No significant change in total cholesterol, triglycerides, HDL, HDL2, HDL3, apoA-I or apoB
• Lp(a) fell from 103 to 65 U/L
• This is the cleanest trial of nandrolone alone in trained athletes and it found essentially nothing on the lipid panel

At 100 mg/week (Kuipers 1991, PMID 1917227):

• HDL fell 25 to 27%, virtually fully reversed 6 weeks after stopping. LDL was not reported.
• The apparent conflict with Hartgens is real and unresolved; both were double-blind and placebo-controlled.

In real-world stacks: If your LDL is up on a deca cycle, look at what is stacked alongside it. Nandrolone is the least likely culprit on the panel.

Baseline lipid panel: Standard practice, and it lets you attribute later changes correctly.

On cycle:

• Check lipids at week 8 to 12. There is no need to test early for LDL specifically on nandrolone.
• Focus the monitoring effort on HDL, which does move, and on prolactin and haematocrit, which are the markers nandrolone genuinely disrupts.

If LDL rises on a deca cycle:

• Look at the rest of the stack. Oral 17-alpha-alkylated compounds are the usual explanation, and both good trials of nandrolone alone found no LDL effect.
• Consider whether an aromatase inhibitor is in play. Suppressing oestradiol removes hepatic LDL receptor support, and nandrolone contributes little oestradiol of its own to spare.

Lipoprotein(a): Worth measuring once if you have never had it done. It is largely genetically determined and does not change with diet, and nandrolone lowering it is one of the few androgen effects on the lipid panel that points the right way.

Do not treat nandrolone as the lipid problem:

• Two randomised trials found no significant LDL effect. If harm reduction on lipids is the goal, dropping the oral from the stack achieves far more than dropping the nandrolone.

Manage the oestradiol side properly:

• Nandrolone contributes little aromatisation, so the oestradiol on a deca-plus-testosterone cycle comes from the testosterone. Suppressing it aggressively with an aromatase inhibitor removes hepatic LDL receptor support without much offsetting benefit.

Standard measures still apply:

• Cardiovascular exercise 30 to 45 minutes, 4 to 5 times per week, which in Sattler's trial was associated with a favourable increase in LDL particle size.
• Soluble fibre 10 to 25 g/day.

Where to actually direct monitoring on nandrolone:

• Prolactin, haematocrit, HDL, and sexual function. These are the endpoints with real trial signal. LDL is not one of them.

Further reading: Nandrolone bloodwork and deca dick